Rheumatology Highlights Report
Therapy of RA with
Non-Biologic DMARDs
 |
 |
|
|
How to Obtain AMA PRA
|
|
 |
||
Release Date: January 5, 2012
Expiration Date: January 5, 2013
Estimated Time of Completion: 15 minutes
Description
The Rheumatology Highlights Report Series is designed for the busy clinician. It provides highlights from key scientific presentations and/or abstracts presented at the national rheumatology meeting. Clinical experts attending this meeting have selected the most significant data to report. Each activity is a 15-minute presentation. Enhancements include downloadable audio and slide sets, and supporting abstracts with expert commentaries. This series offer two methods of participation: on your computer or mobile device.
Learning Objectives
- Review data presented at the 2011 ACR Annual Meeting on the use of non-biologic DMARDs in the treatment of RA.
- Describe the place of non-biologic DMARDs in the RA treatment paradigm.
- Assess the use of non-biologic DMARDs in the context of the treat to target paradigm.
Target Audience
This activity is directed to rheumatologists, immunologists, rheumatology and immunology fellows, clinical researchers, and rheumatology and immunology allied health professionals, including nurse practitioners and physician assistants.
Accreditation
The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Cleveland Clinic Foundation Center for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association Council on Continuing Medical Education for Category 2 credit.
Activity Director
Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Vice Chairman, Department of Rheumatic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, Ohio
Faculty
Allan Gibofsky, MD, JD, FACP, FCLM
Professor of Medicine and Public Health
Weill Medical College of Cornell University
Attending Rheumatologist
Hospital for Special Surgery
New York, New York
Disclosure
In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), the Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.
The following faculty have indicated that they may have a relationship which, in the context of their presentation, could be perceived as a potential conflict of interest:
| Leonard H. Calabrese, DO | ||
| Abbott Laboratories; Amgen; Centocor; Genentech/Roche; Pfizer | Consulting, Teaching & Speaking | |
| BMS; Elan Pharmaceuticals, Inc.; Wyeth | Consulting | |
| Allan Gibofsky, MD | ||
| Ardea; AstraZeneca; Roche Laboratories; Takeda | Consulting | |
| Abbott Laboratories; Amgen; Pfizer, Inc.; UCB | Consulting, Teaching & Speaking | |
| Amgen; Roche Laboratories; Takeda; UCB | Membership on advisory committee or review panels | |
| Abbott Laboratories; Bristol-Myers Squibb Co.; GlaxoSmithKline; Johnson & Johnson; Pfizer, Inc. | Ownership interest (stock, stock options) | |
The Cleveland Clinic Foundation Center for Continuing Education acknowledges educational grants
for partial support of this activity from:
Amgen, Inc.
Pfizer, Inc.
Abbott Laboratories, Inc.
Genentech and Biogen Idec
UCB, Inc
Human Genome Sciences, Inc.
This CME activity was produced by The Cleveland Clinic Foundation Center for Continuing Education
and the RJ Fasenmyer Center for Clinical Immunology.
